| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
52,373,000 |
| Market
Cap: |
2.32(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$30.85 - $52.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 474 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
126,152 |
256,428 |
308,234 |
348,833 |
| Total Sell Value |
$5,873,218 |
$11,298,513 |
$13,114,420 |
$14,216,679 |
| Total People Sold |
4 |
7 |
7 |
7 |
| Total Sell Transactions |
9 |
26 |
34 |
37 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rubino Alan L |
|
– • – |
2021-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
9,394 |
|
- |
|
| Mclaughlin Kevin F |
|
– • – |
2021-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
3,500 |
|
- |
|
| Hagen Heidi |
|
– • – |
2021-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
3,500 |
|
- |
|
| Zerbe Robert L Md |
|
– • – |
2021-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
1,750 |
|
- |
|
| Gilman Steven C |
|
– • – |
2021-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
3,500 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-04-19 |
4 |
AS |
$57.46 |
$2,320,203 |
D/D |
(40,000) |
142,973 |
|
-4% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-04-19 |
4 |
OE |
$25.80 |
$195,125 |
D/D |
7,563 |
173,983 |
|
- |
|
| Mara Joseph Anthony Jr |
Chief Financial Officer |
• – – |
2021-03-31 |
4 |
D |
$55.55 |
$65,438 |
D/D |
(1,178) |
2,822 |
|
- |
|
| Mara Joseph Anthony Jr |
Chief Financial Officer |
• – – |
2021-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
4,000 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-03-30 |
4 |
AS |
$50.56 |
$921,270 |
D/D |
(17,924) |
38,480 |
|
-6% |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-03-30 |
4 |
OE |
$10.95 |
$366,146 |
D/D |
33,438 |
49,584 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-03-30 |
4 |
OE |
$25.80 |
$193,500 |
D/D |
7,500 |
175,050 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-03-29 |
4 |
AS |
$50.93 |
$2,040,254 |
D/D |
(40,000) |
167,550 |
|
-4% |
|
| Rubino Alan L |
|
– • – |
2021-03-19 |
4 |
OE |
$45.20 |
$226,000 |
D/D |
5,000 |
7,644 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-03-01 |
4 |
AS |
$48.01 |
$1,924,227 |
D/D |
(40,000) |
207,550 |
|
10% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-03-01 |
4 |
OE |
$2.65 |
$107,696 |
D/D |
28,355 |
243,742 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2021-02-11 |
4 |
D |
$49.23 |
$74,633 |
D/D |
(1,516) |
5,437 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2021-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
6,953 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-02-11 |
4 |
D |
$49.23 |
$36,332 |
D/D |
(738) |
24,633 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,625 |
25,371 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-02-11 |
4 |
D |
$49.23 |
$160,834 |
D/D |
(3,267) |
219,195 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
222,462 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-02-06 |
4 |
D |
$47.18 |
$12,456 |
D/D |
(264) |
23,746 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
650 |
24,010 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2021-02-06 |
4 |
D |
$47.18 |
$42,085 |
D/D |
(892) |
3,453 |
|
- |
|
402 Records found
|
|
Page 9 of 17 |
|
|
1.43 (3.12%) 
